Doctors test re-engineered immune cells to fight advanced cancers
NCT ID NCT06334783
Summary
This early-stage trial tested a personalized treatment called Tumor-Infiltrating Lymphocyte (TIL) therapy for adults with advanced solid tumors that hadn't responded to standard treatments. Doctors collected immune cells from a patient's own tumor, grew large numbers of them in a lab, and then infused them back into the patient to attack the cancer. The study aimed to see if this approach was safe and could help control the disease, but it was terminated after enrolling only 5 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China
-
Nanjing Jinling Hospital
Nanjing, Jiangsu, 210000, China
-
Wowen's hospital, School of medicine, Zhejiang University
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.